Results 171 to 180 of about 681,792 (231)

Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. [PDF]

Nanomedicine, 2018
Kallus S, Englinger B, Senkiv J, Laemmerer A, Heffeter P, Berger W, Kowol CR, Keppler BK.   +7 more
europepmc   +1 more source

FGFR Inhibitor TAS-120 [PDF]

, 2020
openaire   +1 more source

Pan FGFR Inhibitor PRN1371 [PDF]

, 2020
openaire   +1 more source

Synthesis, biological evaluations and molecular modelling studies of novel indolin-2-ones designing as FGFR inhibitors. [PDF]

Saudi Pharm J, 2019
Çoban G, Aydın Köse F.
europepmc   +1 more source

FGFR Inhibitor Debio 1347 [PDF]

, 2020
openaire   +1 more source

FGFR signaling and apoptotic regulation in cancer: links to immune evasion, therapeutic resistance, and treatment re-engagement. [PDF]

Front Immunol
Hu Y, Zhang X, Liu W, Wei Y, Xue J, Ma X, Cao Y, Li P.   +7 more
europepmc   +1 more source

Emerging Roles of FGFR3 and FGF23-Associated Signaling in Renal Fibrosis: Molecular Integration, Clinical Correlates, and Therapeutic Perspectives. [PDF]

Biomolecules
Fu Y, Wang H, Wang L, Wang H.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pemigatinib, a Potent Inhibitor of FGFRs for the Treatment of Cholangiocarcinoma

Future Oncology, 2020
The prognosis of patients affected by cholangiocarcinoma is classically poor. Until recently, chemotherapeutic drugs were the only systemic treatment option available, leading to an overall survival lower than 1 year. In recent decades, different genetic alterations have been identified as playing a key role in the oncogenic signaling.
Valeria Merz, Camilla Zecchetto, Davide Melisi   +2 more
openaire   +2 more sources